Loading...
QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis
Sunitinib is widely used as a first-line treatment for advanced renal cell carcinoma (RCC). However, a number of patients with RCC who receive sunitinib develop drug resistance; and the biological mechanisms involved in resistance to sunitinib remain unclear. It has previously been suggested that th...
Na minha lista:
| Udgivet i: | Int J Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
D.A. Spandidos
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8208629/ https://ncbi.nlm.nih.gov/pubmed/34036385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2021.5228 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|